Superbug infections kill more people now than HIV/AIDS or malaria. We need new antibiotics and other drugs, but developers lack incentives. A new policy could fix that.
BioVersys AG announces extension of its Series C investment round to CHF 32.6 million as the AMR Action Fund makes its first European-based investmentBASEL, Switzerland, January 05, 2023 / B3C newswire / BioVersys AG, a privately held clinical stage, multi-asset Swiss pharmaceutical company focusing on research a.
AMR Action Fund invests in Swiss antibiotic maker umn.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from umn.edu Daily Mail and Mail on Sunday newspapers.